2023-08-16 10:07:44 ET
A North Carolina-based %Biotech company started Wednesday’s session with a bang after the company announced the completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to %AzercabtageneZapreleucel (azer-cel), the company’s lead allogeneic CAR T candidate, for cancer.
Traders were extremely optimistic on the news, as shares of %PrecisionBioSciences (Nasdaq: ) quickly traded up to $0.609/share (+14.82%) in the first minute of the session. This move could be an indication of things to come!
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm.